Top Ten most popular articles on this week

pharmafile | September 20, 2019 | News story | Medical Communications  

Friday time! This past week has seen numerous potential breakthroughs including a prostate drug that could halt Parkinson’s disease as well as new MS drugs beating out old rivals in trials. Here’s a rundown of the top 10 articles on pharmafile this past week:

10. Swiss biotech raises $16m for ‘undelivery mechanism’ in rare liver disease

A new method from Swiss Biotech Versantis promises to give far better immediate care and offer a treatment for a couple of rare forms of liver disease that leave patients without options aside from transplantation

9. New agreement gives AstraZeneca full responsibility for Linzess in China

AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals in China for Linzess (linaclotide), a first-in-class new treatment for patients with irritable bowel syndrome with constipation (IBS-C).

8. US, Canada and Australia simultaneously fast-track Keytruda/Lenvima combo for endometrial cancer

The FDA has acted under a new initiative in collaboration with the Australian Therapeutic Goods Administration (TGA) and Health Canada, conducting simultaneous review in all three countries to award accelerated approval to the combination of Keytruda (pembrolizumab)and Eisai’s Lenvima (lenvatinib) for the treatment of advanced endometrial carcinoma.

7. Enlarged prostate drug may slow Parkinson’s disease

A surprising find has led researchers to see that a drug used to treat enlarged prostates may also work as a powerful medication against Parkinson’s disease, according to an international team of scientists.

6. Janssen’s Ponesimod outclasses Sanofi’s Aubagio in relapsing MS

Johnson & Johnson subsidiary Janssen have announced results from its Phase 3 OPTIMUM trial showing superior efficacy to Sanofi’s Aubagio (teriflunomide) with its investigational drug ponesimod in adults with relapsing multiple sclerosis (MS).

5. Ardelyx’s Ibsrela wins FDA approval for IBS-C

Ardelyx announced that it has received FDA approval for its NHE3 sodium transport inhibitor Isbrela (tenapanor) for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.

4. Lundbeck acquires Alder in $2bn migraine treatment move

Lundbeck is to buy Alder Biopharmaceuticals for $2 billion enhancing its leading portfolio of brain disease therapies through the acquisition of eptinezumab, an investigational monoclonal antibody for migraine prevention.

3. Opioid drugmaker Purdue Pharma files for bankruptcy

In the face of thousands of lawsuits in its role in the opioid addiction crisis, Purdue Pharma   announced yesterday that it has filed for bankruptcy, stating funds would go to the 24 states and thousands of cities and counties that are seeking damages from the sale of its opioid painkiller drug OxyContin.

2. New APPG report on access to cutting edge medicines

A new report from the All-Party Parliamentary Groups (APPG) is urging the life science community to work together to speed up access to cutting-edge medicines in the UK.

1. Novartis announce robust Phase 3 trials for ofatumumab in MS

Novartis’ multiple sclerosis candidate has demonstrated strong results in its Phase 3 ASCLEPIOS trials meeting primary endpoints and slashing the risk of progression by 30% compared to Sanofi’s Aubagio.

Related Content

No items found

Latest content